Use of tumor pY1234/1235MET/total MET ratio as a PD biomarker to guide tepotinib dose selection was further supported in an independent study using a MET-amplified gastric cancer xenograft model (SNU-5; ref. 39). Here, MET is linked to gastric cancer.